Warning Letter Pilot Could Muddy Compliance Waters, Attorney Maintains
This article was originally published in The Gray Sheet
Executive Summary
FDA's proposed warning letter pilot program could have the unintended effect of making it harder for industry to interpret certain compliance-related "gray areas," Thomas Muldoon, a partner in the Chicago law firm of Burditt & Radzius, asserted Oct. 27 at the Regulatory Affairs Professionals Society annual meeting in Washington, D.C.
You may also be interested in...
CBER Warning Letter Pilot, Other Device Initiatives Recommended
FDA's Center for Biologics Evaluation and Research should adopt the Center for Device and Radiological Health's warning letter pilot program for non-blood related devices, Gen-Probe Senior Director of Regulatory Affairs Glen Freiberg told an Oct. 6 session of the Regulatory Affairs Professionals Society annual meeting in Washington, D.C.
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.